Company research
Aspira Women's Health Inc.
CIK 926617Updated Sep 24, 2026
SecurityAWHL · OTC · equity
Name history
VERMILLION, INC. · through Jun 10, 2020CIPHERGEN BIOSYSTEMS INC · through Aug 17, 2007
AWHL price & chart
Loading TradingView…
OTC:AWHL on TradingView ↗About the company
We are dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
D filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,456,000Source | 5,491,000Source | 6,262,000Source | 23,942,000Source |
| Property, Plant and Equipment, NetUSD | 47,000Source | 69,000Source | 165,000Source | 417,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,755,000Source | 1,769,000Source | 2,597,000Source | 20,551,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,207,000Source | 990,000Source | 1,459,000Source | 1,201,000Source |
| Inventory, NetUSD | 256,000Source | 326,000Source | 227,000Source | 280,000Source |
| Assets, CurrentUSD | 4,063,000Source | 4,183,000Source | 5,280,000Source | 22,976,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 845,000Source | 1,098,000Source | 997,000Source | 944,000Source |
| Operating Lease, Right-of-Use AssetUSD | 980,000Source | 1,194,000Source | 528,000Source | 299,000Source |
| Other Assets, NoncurrentUSD | 56,000Source | 45,000Source | 31,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,388,000Source | 8,054,000Source | 8,627,000Source | 12,764,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 43,000Source | 17,000Source | 11,000Source | 8,000Source |
| Additional Paid in CapitalUSD | — | — | 515,927,000Source | 508,192,000Source |
| Retained Earnings (Accumulated Deficit)USD | -544,177,000Source | -531,397,000Source | -518,303,000Source | -497,022,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | -531,397,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | -6,932,000Source | -2,563,000Source | -2,365,000Source | 11,178,000Source |
| Additional Paid in Capital, Common StockUSD | 537,202,000Source | 528,817,000Source | — | — |
| Liabilities and EquityUSD | 5,456,000Source | 5,491,000Source | 6,262,000Source | 23,942,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,465,000Source | 5,468,000Source | 5,119,000Source | 7,297,000Source |
| Operating Lease, Liability, CurrentUSD | 202,000Source | 7,000Source | 159,000Source | 73,000Source |
| Accounts Payable, CurrentUSD | 1,237,000Source | 2,173,000Source | 1,261,000Source | 1,893,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,008,000Source | 1,248,000Source | 427,000Source | 293,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,297,000Source | 2,445,000Source | 2,863,000Source | 4,988,000Source |
| Deferred Tax Liabilities, NetUSD | 233,000Source | 285,000Source | 123,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 236,000Source | 229,000Source | 166,000Source | 343,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 1,041,000Source | 1,278,000Source | 1,430,000Source | 2,426,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 199,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 531,000Source | 1,494,000Source | 1,724,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 217,000Source | -469,000Source | 214,000Source | — |
| Increase (Decrease) in InventoriesUSD | -68,000Source | 99,000Source | -89,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -936,000Source | 912,000Source | 380,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,029,000Source | -12,113,000Source | -15,894,000Source | — |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -401,000Source | -37,000Source | -24,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 16,000Source | 37,000Source | 24,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 7,416,000Source | 11,064,000Source | 5,216,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -14,000Source | -1,086,000Source | -10,702,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 1,769,000Source | 2,855,000Source | 20,801,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 34,000Source | 49,000Source | 45,000Source | — |
| Income Taxes Paid, NetUSD | 10,712Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 531,000Source | 1,494,000Source | 1,724,000Source | — |
| Amortization of Debt Issuance CostsUSD | — | — | 258,000Source | — |
| Amortization of Intangible AssetsUSD | 75,000Source | — | — | — |
| DepreciationUSD | 37,000Source | 92,000Source | 199,000Source | — |
| Depreciation, Amortization and Accretion, NetUSD | 112,000Source | 92,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -1,000Source | -41,000Source | -28,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 1,000,000Source | — |
| General and Administrative ExpenseUSD | 7,964,000Source | 10,345,000Source | 12,267,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -12,780,000Source | -13,094,000Source | -16,690,000Source | — |
| Nonoperating Income (Expense)USD | -4,867,000Source | 3,184,000Source | 2,162,000Source | — |
| Operating ExpensesUSD | 13,828,000Source | 21,757,000Source | 24,114,000Source | — |
| Other Nonoperating Income (Expense)USD | 1,809,000Source | 1,871,000Source | 485,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | 202,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 9,216,000Source | 9,182,000Source | 9,154,000Source | — |
| Cost of RevenueUSD | 3,301,000Source | 3,703,000Source | 3,892,000Source | 3,861,000Source |
| Operating Income (Loss)USD | -7,913,000Source | -16,278,000Source | -18,852,000Source | -31,138,000Source |
| Other Nonoperating Income (Expense)USD | 1,809,000Source | 1,871,000Source | 485,000Source | -468,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -12,780,000Source | 13,094,000Source | 16,700,000Source | 29,885,000Source |
| Net Income (Loss) Attributable to ParentUSD | -12,780,000Source | -13,094,000Source | -16,690,000Source | -29,885,000Source |
| Earnings Per Share, BasicUSD per share | -0.37Source | -0.93Source | -1.81Source | -3.85Source |
| Earnings Per Share, DilutedUSD per share | -0.37Source | -0.93Source | -1.81Source | -3.85Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 34,102,760Source | 14,134,626Source | 9,233,306Source | 7,769,109Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 34,102,760Source | 14,134,626Source | 9,233,306Source | 7,769,109Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 75,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | 0Source | — | 0Source | 0Source |
| General and Administrative ExpenseUSD | 7,964,000Source | 10,345,000Source | 12,267,000Source | 14,629,000Source |
| Gross ProfitUSD | 5,915,000Source | 5,479,000Source | 5,262,000Source | 4,323,000Source |
| Interest Income (Expense), NetUSD | -41,000Source | -33,000Source | 48,000Source | 17,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -29,885,000Source |
| Nonoperating Income (Expense)USD | -4,867,000Source | 3,184,000Source | 2,162,000Source | — |
| Operating ExpensesUSD | 13,828,000Source | 21,757,000Source | 24,114,000Source | 35,461,000Source |
| Other IncomeUSD | — | 2,000,000Source | — | — |
| Research and Development ExpenseUSD | 2,878,000Source | 3,266,000Source | 4,035,000Source | 5,917,000Source |
| Selling and Marketing ExpenseUSD | 2,986,000Source | 8,146,000Source | 7,812,000Source | 14,915,000Source |
Offerings
Registration 333-292512
Registration 333-290633
Registration 333-286561
Registration 333-284182
Underwriters: Issuance Date, August 25, 2022
Filing attachments
awhl-20260529xex4d1.htm · 8-K · 2026-06-09
EX-4.1 2 awhl-20260529xex4d1.htm EX-4.1 RE RE Exhibit 4.1 FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UN…
Read attachment ↗awhl-20260520xex99d1.htm · 8-K · 2026-05-26
EX-99.1 3 awhl-20260520xex99d1.htm EX-99.1 Exhibit 99.1 Aspira Women’s Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women’s Health Collaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable clinical validation AUSTIN, Texas, and CLEVELAND, Ohio, May 26, 2026 - Aspira Women’s Health Inc. (OTCQX: AWHL) (“Aspira” or the “Company”), a bio-analytical company focused on the develop…
Read attachment ↗awhl-20251229xex99d1.htm · 8-K · 2025-12-31
EX-99.1 2 awhl-20251229xex99d1.htm EX-99.1 Exhibit 99.1 Investor Presentation OTCQX: AWHL Forward -looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this presentation, including statements regarding Aspira Women’s Health, Inc.’s (the “Company’s” or Aspira”) strategy, future, operations, future financial position, projected costs, prospe…
Read attachment ↗awhl-20251114xex99d1.htm · 8-K · 2025-11-14
EX-99.1 2 awhl-20251114xex99d1.htm EX-99.1 Exhibit 99.1 Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update AUSTIN, Texas, November 14, 2025 (GLOBE NEWSWIRE) - Aspira Women’s Health Inc. (“Aspira”) (OTCQX: AWHL), an AI enhanced bio-analytics based women’s health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and nine-month periods ended Sept…
Read attachment ↗awhl-20250919xex4d1.htm · 8-K/A · 2025-11-03
EX-4.1 2 awhl-20250919xex4d1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO…
Read attachment ↗ex4-1.htm · 8-K · 2025-09-25
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗